sellWeak cluster of 610b5-1 plan
Sekar Kathiresan sold $41k of VERV
Chief Executive Officer at Verve Therapeutics, Inc.. 9,822 shares at an average of $4.15, traded Apr 2, 2025, filed Apr 3, 2025.
Warning score
11Value
$41k
9,822 shares
Holdings after
346,686
-3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +6Trade size$41k at market
- 0Share of holdings soldSold 2.8% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-050563, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | MOption exercise Common Stock10b5-1 | +33,000 | - | - | 356,508 | Apr 3, 2025 |
| Apr 2, 2025 | SOpen-market sale Common Stock10b5-1 | -9,822 | $4.15 | $41k | 346,686 | Apr 3, 2025 |
| Apr 1, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -33,000 | $0.00 | $0 | 99,000 | Apr 3, 2025 |
Related signals
Other insiders at Verve Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Verve Therapeutics, Inc. | Andrew D. Ashe See Remarks | $11k 2,681 shares | -1% | |
| 7Weak | Verve Therapeutics, Inc. | Allison Dorval Chief Financial Officer | $14k 3,350 shares | -20% | |
| 0Weak | Verve Therapeutics, Inc. | Troy Lister Chief Scientific Officer | $9,084 2,189 shares | -24% | |
| 0Weak | Verve Therapeutics, Inc. | Joan Nickerson Chief Administrative Officer | $12k 2,777 shares | -14% | |
| 0Weak | Verve Therapeutics, Inc. | Jason Politi Chief Technical Ops. Off. | $13k 3,235 shares | -19% | |
| 7Weak | VERVsell Verve Therapeutics, Inc. | Allison Dorval Chief Financial Officer | $3,130 555 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.